Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Get the latest updates from Investor Update directly as they happen.
Follow now 373 followers
Last updated about 9 hours ago
about 9 hours ago
Agreement offers potential best-in-class targeted protein degrader therapy option for people living...
6 days ago
Filing acceptance, under priority review, based on phase III data showing giredestrant...
7 days ago
We are pleased to invite investors and analysts to participate in our...
7 days ago
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its...
18 days ago
The Roche Investor Relations team would like to invite you to an...
20 days ago
New giredestrant data from the lidERA study on its potential as a...
27 days ago
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with...
about 1 month ago
We are pleased to invite investors and analysts to participate in our...
about 1 month ago
PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow...
about 1 month ago
The Roche Investor Relations team would like to invite you to an...
about 1 month ago
The Roche Investor Relations team would like to invite you to the...
about 2 months ago
Group sales were +6% at constant exchange rates (CER)1, -5% when reported...